QALYs, standard gambles, and the expected budget constraint

被引:9
作者
Blomqvist, Å [1 ]
机构
[1] Univ Western Ontario, Dept Econ, London, ON N6A 5C2, Canada
关键词
QALYs; CUA; standard gambles; contingent markets;
D O I
10.1016/S0167-6296(01)00116-3
中图分类号
F [经济];
学科分类号
02 ;
摘要
This paper shows that when quality adjustment factors for use in constructing QALY indices are established through answers to standard-gamble questions or similar methods, the assumptions that are made by respondents about the financial consequences of changing probabilities of illness and death are critically important for the use of QALYs in cost-utility analysis (CUA). It qualifies Meltzer's [Journal of Health Economics 16 (1997) 33] result that the cost per quality-adjusted life-year (QALY) for life-saving medical interventions should include the future consumption of those who would otherwise not have survived, by showing that its validity depends on how the QALY index has been established. The paper also shows that, contrary to a widely held notion, allocation of a fixed health care budget through CUA does not generally result in a second-best efficient allocation. Another finding is that failure to specify carefully what respondents to standard-gamble questions are supposed to assume about the financial consequences of ill health may result in a bias against providing care to older individuals. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:181 / 195
页数:15
相关论文
共 13 条
[1]   Life-cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost-benefit analysis? [J].
Bleichrodt, H ;
Quiggin, J .
JOURNAL OF HEALTH ECONOMICS, 1999, 18 (06) :681-708
[2]  
Dolan P, 2000, HANDB ECON, V17, P1723
[3]   The time trade-off: A note on the effect of lifetime reallocation of consumption and discounting [J].
Dolan, P ;
Jones-Lee, M .
JOURNAL OF HEALTH ECONOMICS, 1997, 16 (06) :731-739
[4]   Economic foundations of cost-effectiveness analysis [J].
Garber, AM ;
Phelps, CE .
JOURNAL OF HEALTH ECONOMICS, 1997, 16 (01) :1-31
[5]  
Johannesson M, 1996, HEALTH ECON, V5, P279, DOI 10.1002/(SICI)1099-1050(199607)5:4<279::AID-HEC218>3.0.CO
[6]  
2-J
[7]  
Kaplan R, 1995, Valuing Health Care: Costs, Benefits, and Effectiveness of Pharmaceuticals and Other Medical Technologies, P31, DOI [10.1017/CBO9780511625817.003, DOI 10.1017/CBO9780511625817.003]
[8]   On valuing morbidity, cost-effectiveness analysis, and being rude [J].
Kenkel, D .
JOURNAL OF HEALTH ECONOMICS, 1997, 16 (06) :749-757
[9]   Accounting for future costs in medical cost-effectiveness analysis [J].
Meltzer, D .
JOURNAL OF HEALTH ECONOMICS, 1997, 16 (01) :33-64
[10]  
Phelps C E, 1991, Int J Technol Assess Health Care, V7, P12